Mynvax, a clinical stage vaccine biotechnology company, was founded with the singular vision of developing novel, improved, recombinant, thermostable vaccines to protect against respiratory viral infections.
Mynvax was named as one of the seven Indian vaccine companies working on developing vaccines for COVID-19. Mynvax has successfully demonstrated its vaccine design capabilities by quickly developing a thermotolerant COVID-19 vaccine formulation, efficacious against earlier and current viral variants, and accessible to low and lower-middle-income countries.
Founded in 2017, Mynvax has a young team of highly qualified scientists. Mynvax has received financial support from SID, the incubation centre of the Indian Institute of Science, BIRAC, Department of Biotechnology, Government of India, and various early-stage Indian and global investors. Mynvax has initiated commercial development partnerships with vaccine manufacturers.
Using its novel intellectual property, patents, and scientific know-how in the area of protein stabilization and design, Mynvax will deploy its novel vaccines for improved protection against respiratory viral diseases.
